Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.

Xiaojing XuYiyi YuMinna ShenMengling LiuShengchao WuLi LiangFei HuangChenlu ZhangWei GuoTian-Shu Liu

Published in: BMC cancer (2020)

Analyzing mutations in plasma could provide a more comprehensive overview of the mutational landscape than analyzing mutations in tissue. The cfDNA concentration could be a quantitative biomarker of tumor burden and could predict survival in Chinese patients with mCRC.

Keyphrases

metastatic colorectal cancer
end stage renal disease
newly diagnosed
ejection fraction
peritoneal dialysis
high resolution
risk factors
free survival
circulating tumor
single molecule
cell free
patient reported outcomes